Asset Details
Do you wish to reserve the book?
Trastuzumab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trastuzumab
Do you wish to request the book?
Trastuzumab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trastuzumab
2008
Overview
Trastuzumab (Herceptin®) is a monoclonal antibody approved for the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).
Well designed clinical trials in women with early breast cancer have demonstrated that 1 years’ therapy with adjuvant intravenous trastuzumab (a loading dose followed by 6 mg/kg every 3 weeks or 2 mg/kg weekly) significantly improves disease-free survival and overall survival compared with observation (subsequent to chemotherapy) or chemotherapy alone in women with HER2-positive disease. In the HERA trial, disease-free survival was estimated to improve by 6.3% at 3 years in the trastuzumab group compared with the observation group.
Trastuzumab is generally well tolerated. The most common adverse events are infusion-related symptoms, such as fever and chills, which usually occur with administration of the first dose. Cardiotoxicity occurs in a small proportion of patients receiving trastuzumab, particularly when coadministered with anthracyclines, and cardiac assessment is recommended for all patients at baseline and at 3-monthly intervals.
In modelled cost-effectiveness analyses based on data from clinical trials in patients with HER2-positive early breast cancer, adjuvant trastuzumab was predicted to be cost effective from a healthcare payer or societal perspective in several countries. Incremental costs per QALY or life-year gained with trastuzumab administered subsequent to or concurrent with chemotherapy compared with chemotherapy alone were consistently within accepted local thresholds for cost effectiveness. Sensitivity analyses demonstrated that these results remained generally robust to plausible changes in key model assumptions.
In conclusion, in patients with HER2-positive early breast cancer, the addition of adjuvant trastuzumab is clinically effective in improving disease-free survival. Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of adjuvant trastuzumab for 1 year as a cost-effective treatment relative to chemotherapy alone in this patient population.
Publisher
Springer International Publishing,Adis International,Springer Healthcare | Adis,Springer,Springer Nature B.V
Subject
Adis Pharmacoeconomic Drug Evaluation
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - economics
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - economics
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - economics
/ Breast Neoplasms - metabolism
/ Costs
/ Drugs
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Kinases
/ Medicine
/ Patients
/ Pharmacoeconomics and Health Outcomes
/ Pharmacology. Drug treatments
/ Receptor, ErbB-2 - metabolism
/ Studies
/ Surgery
/ Tumors
